Focus Diagnostics
Founded Year
1978Stage
Acquired | AcquiredTotal Raised
$76.59MValuation
$0000Revenue
$0000About Focus Diagnostics
Focus Diagnostics develops diagnostic and database services and products for infectious and immunological diseases. On July 14th, 2006, Focus Diagnostics was acquired by Quest Diagnostics.
Missing: Focus Diagnostics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Focus Diagnostics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Focus Diagnostics Patents
Focus Diagnostics has filed 9 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
4/29/2014 | 8/29/2017 | Molecular biology, Virology, Transcription factors, Biotechnology, Molecular biology techniques | Grant |
Application Date | 4/29/2014 |
|---|---|
Grant Date | 8/29/2017 |
Title | |
Related Topics | Molecular biology, Virology, Transcription factors, Biotechnology, Molecular biology techniques |
Status | Grant |
Latest Focus Diagnostics News
Dec 29, 2020
Saluggia (Italy) - May 13, 2016 – DiaSorin S.p.A. (FTSE Italy: DIA) today announced the completion of the transaction to acquire the Focus Diagnostics’ immunodiagnostic and molecular diagnostic products business (“Focus”) from Quest Diagnostics (NYSE: DGX), initiated with a binding purchase agreement signed on March 29, 2016. DiaSorin paid to Quest Diagnostics $300 million in cash for all the tangible and intangible assets of Focus used by the latter to develop, manufacture and distribute its molecular diagnostic products and its traditional immunoassay ELISA products, including among other relevant intellectual property, contracts and customer list. Focus’ product lines include the Simplexa™ molecular product line, HerpeSelect® HSV serology, and a line of DxSelect™ IFA and ELISA assays that will continue to be manufactured by the relevant facility in Cypress, California, USA. The transaction does not include Quest Diagnostics’ diagnostic information services laboratories currently operating under the Focus Diagnostics brand. The transaction’s main terms and conditions are those already made available by both parties to the public on March 30, 2016. Wendy Bost (Media) 973-520-2800 (US) About DiaSorin: Headquartered in Italy and listed in the FTSE Mid Cap Index, DiaSorin is a global leader in the In Vitro Diagnostics (IVD) field. For over 40 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnostics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnostics market and new tests in the molecular diagnostics markets which identify DiaSorin Group as the IVD “diagnostics specialist”. www.diasorin.com About Quest Diagnostics: Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com .
Focus Diagnostics Frequently Asked Questions (FAQ)
When was Focus Diagnostics founded?
Focus Diagnostics was founded in 1978.
Where is Focus Diagnostics's headquarters?
Focus Diagnostics's headquarters is located at 5785 Corporate Avenue, Cypress.
What is Focus Diagnostics's latest funding round?
Focus Diagnostics's latest funding round is Acquired.
How much did Focus Diagnostics raise?
Focus Diagnostics raised a total of $76.59M.
Who are the investors of Focus Diagnostics?
Investors of Focus Diagnostics include Quest Diagnostics and Sprout Group.
Who are Focus Diagnostics's competitors?
Competitors of Focus Diagnostics include Affidea, Integrated Diagnostics, Veredus Laboratories, Epocal, Ortho Kinematics and 16 more.
Compare Focus Diagnostics to Competitors
ViralTest offers molecular-based diagnostics development for niche infectious diseases markets.
Lifelinelab s.r.l. started its activities in April 2003, thanks to the commitment of three managers coming from the ex Diagnostic Division Manufacturing Plant of Alfa Wassermann S.P.A. First step has been to secure raw materials, and equipment for R&D and Manufacturing of products and services in the field of Human in Vitro Diagnostics. nnnnnFirst diagnostic reagents were manufactured, in this site, over 40 years ago, through the bravery and the enterprising spirit of Prof. Balducci ex Managing Director of Virology Laboratory of "Istituto Superiore di Sanitu00e0". First products were based on tissue colture technology included a line of complement fixation antigens. Since then, the company developed methods and products, covering almost all the fields of Human in Vitro Diagnostics, from Clinical Chemistry to Immunochemistry. The mostly developed sector has been that of Infectious Diseases with particular regard to Viral pathologies. Most products have been developed using biological raw materials derived from in house, in vivo or in vitro, productions. Nowadays the company aims to face and develop markets with consolidate and emerging technologies such as Microarrays using a chemistry patented and designed to covalently bind either Protein or Nucleic acids which aims to allow the development of extremely sophisticated analysis in the emerging applications of proteomics and genomics.
Chemogen develops rapid diagnostic tests for infectious diseases, currently focused on TB
Hx Diagnostics offers rapid diagnostics for seasonal and emerging infectious diseases.
At Nanogen, Inc., the company develop diagnostic products that enable physicians to deliver improved patient care. The company's products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and infectious diseases. These products include molecular diagnostic kits and reagents, and rapid test kits, which can be used in urgent care settings or at the point-of-care. Nanogen has pioneered developments in areas involving biomarkers, molecular biology and nanotechnology. The company's business focus is to bring better results to diagnostics and healthcare.
AngioLogix is a provider of cardiovascular health diagnostics.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.